Hinova Self-developed Prostate Cancer Drug HC-1119 Enters Global Multicentered Phase III clinical trial

Time:2019-08-01 Source:海创药业 Hits:1262

HC-1119, a novel molecular entity, is a small molecule AR antagonist developed by Hinova for the treatment of advanced prostate cancer. In 2016, its Phase I clinical trial was approved by the National Medical Products Administration (NMPA) and has completed by now. An IND application was submitted to the U.S. in January 2019 and was approved for direct entry into Phase III clinical studies in February of the same year. Global multicentered Phase III trials of HC-1119 are currently underway in the United States, China, the European Union, Australia, Canada, Russia, etc.

About Hinova

Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.